Delayed Graft Function Raises Graft Loss Risk in Expanded-Criteria Donor Kidney Recipients—But Not Standard Donors

0
0
0

Delayed Graft Function Raises Graft Loss Risk in Expanded-Criteria Donor Kidney Recipients—But Not Standard Donors

Kidney transplantation is the best treatment for end-stage renal disease (ESRD), but demand far outpaces supply. To close the gap, doctors increasingly use expanded-criteria donors (ECDs)—older adults (60+) or those over 50 with health issues like hypertension or high creatinine. While ECDs save lives, they carry a higher risk of delayed graft function (DGF)—a common complication where the new kidney needs dialysis within the first week post-transplant.

But does DGF actually shorten graft survival? A new multicenter study from China’s top transplant centers answers this question—with surprising results for ECD vs. standard-criteria donor (SCD) recipients.

What the Study Did

Researchers analyzed data from 284 deceased donors and 541 recipients across three hospitals (2012–2017, 5-year follow-up). They compared:

  • DGF rates in ECD vs. SCD kidneys
  • How DGF impacts long-term graft survival
  • Factors that protect against DGF or graft loss

Key definitions:

  • ECD: Donors ≥60, or 50–59 with 2+ issues (hypertension, creatinine >1.5 mg/dL, cerebrovascular death).
  • SCD: Donors without these risks.
  • DGF: Need for dialysis in the first 7 days after transplant.
  • Warm Ischemia Time (WIT): Time from donor heart stop to kidney cooling—longer times damage organs.

The Big Findings

  1. ECD Kidneys Have Higher DGF Risk
    29.2% of ECD recipients developed DGF, vs. 17.1% of SCD recipients. That’s a 65% higher risk for ECDs.

  2. DGF Only Harms ECD Graft Survival

    • For SCD recipients: DGF didn’t affect 5-year graft survival (95.8% with DGF vs. 95.4% without—no significant difference).
    • For ECD recipients: DGF cut survival drastically—71.4% vs. 97.6% without DGF. The adjusted risk of graft loss was nearly 2x higher (hazard ratio [HR] = 1.89).

  3. Anti-Thymocyte Globulin (ATG) Protects Against DGF and Graft Loss
    Induction therapy with ATG (a drug that reduces immune rejection) lowered DGF risk by 64% (odds ratio [OR] = 0.36) for all recipients. For ECDs, ATG also boosted long-term survival (HR = 0.31—70% lower risk of graft loss).

  4. Long WIT (>18 Min) Raises DGF and Graft Loss Risk
    WIT over 18 minutes doubled DGF risk (OR = 1.56) and increased graft loss risk by 34% (HR = 1.34). ECD recipients with long WIT had a 47% DGF rate and 16% graft loss rate—far higher than those with shorter WIT.

Why Does DGF Hit ECD Kidneys Harder?

ECD kidneys are already vulnerable:

  • More sensitive to damage: Ischemia-reperfusion injury (from blood flow stopping/restarting) harms older or unhealthy kidneys more.
  • Poorer repair ability: ECD kidneys have fewer healthy nephrons (kidney filters) and can’t bounce back from DGF as well.
  • AKI-CKD link: Many ECDs have pre-existing chronic kidney disease (CKD) from hypertension or proteinuria. Acute injury (DGF) on top of CKD accelerates decline—ECD recipients with DGF were 2x more likely to develop new proteinuria and lose kidney function over time.

What This Means for Patients and Doctors

  • ECD Recipients: DGF is a red flag for long-term graft health. Doctors should prioritize ATG induction therapy to lower DGF risk and improve survival.
  • Donor Management: Keeping WIT under 18 minutes is critical—especially for ECD kidneys. Shorter WIT cuts DGF risk by half (13.8% vs. 47.3% for ECDs).
  • Transplant Teams: This study resolves conflicting research—DGF matters for ECDs, not SCDs. It gives doctors clear data to optimize ECD kidney use and counsel patients.

Limitations and Next Steps

The study is retrospective (relies on past records), so it can’t prove cause and effect—only associations. Future research should test ATG and WIT reduction in randomized trials to confirm results.

Study Details

This research was led by Fei Han (Third Affiliated Hospital of Sun Yat-sen University) and Min-Zhuan Lin (Third Affiliated Hospital of Guangzhou Medical University), with colleagues from Jilin University. It was funded by China’s National Key R&D Program and National Natural Science Foundation, with no conflicts of interest.

Original study: Han F, et al. Delayed graft function is correlated with graft loss in recipients of expanded-criteria rather than standard-criteria donor kidneys: a retrospective, multicenter, observation cohort study. Chinese Medical Journal, 2020. doi.org/10.1097/CM9.0000000000000666

For patients waiting for a kidney, these findings offer hope: ECD kidneys can work—but managing DGF and WIT is key to making them last. For doctors, it’s a roadmap to safer, more effective transplant care.

Was this helpful?

0 / 0